Raising the Bar for Advanced Knee Assessment Technology with Michelle Laflamme, CEO of Emovi

Trends in Med Tech

In this episode I spoke with Michelle Laflamme, CEO of Emovi, a medical device company dedicated to developing and commercializing advanced technologies for the assessment of knee pain. Emovi began in 2008 when Michelle, a practicing lawyer at the time, was reviewing the clinical evidence behind its signature device, KneeKG, that helps clinicians to better diagnose the root causes of knee pain and make data driven treatment decisions. Michelle recognized that the technology could fill gaps in the treatment pathway and bring huge value to patients. Over the next few years, Michelle selected a team of passionate and talented experts to take the company through numerous validation studies (they have more than 100 peer reviewed papers), to demonstrate effectiveness as a clinical decision tool and to build strategic partnerships with key stakeholders, including several university research centres and a full clinical advisory board. Over 10,000 patients have used KneeKG in their care pathways to help treat knee pain and get back to their normal activity. With plans to expand access in Canada and the US, many more patients will soon be using and benefiting from the device. Her passion for entrepreneurship and helping patients really stood out to me. She also spoke about her work in mentoring other entrepreneurs through an accelerator she founded, and through her roles on several boards.

To learn even more about Emovi you can visit the company website at emovi.ca. You can also follow the company and get updates on its activity on Twitter @knee_KG , and follow Emovi on LinkedIn.